IDEAYA Biosciences UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, fantastic. If we are ready to go, thank you so much for joining us on our next session. I am Michael Yee, Senior Biotechnology Analyst here at UBS, and we are excited to have the Chief Executive Officer of IDEAYA Biosciences here, Yujiro Hata, with us. IDEAYA is an exciting time right now because the company is on the brink of filing and getting potential approval for their lead drug, I say daro, but darovasertib, for metastatic uveal melanoma, a small molecule with tremendous efficacy and positive phase II results. So, that may happen in 2027, on the brink of your first approval. In addition, there is so much pipeline to talk about, I am going to have to limit it in our 25-minute discussion because there is not enough time. You are hosting an R&D analyst event later today as well, so we get a little preview of that today.
Without further ado, maybe, Yujiro, you could set the table for us first to just obviously talk about the most important things going on at IDEAYA with, perhaps we will hear more later at the R&D day, but set the table for us a little bit about your current pipeline.
Well, great. First, thank you, Mike, for hosting us, and also congratulations to UBS on the inaugural event in London this week. IDEAYA Biosciences, as you mentioned, 2026 has been a transformational year for us. We filed our first NDA, also reported our top-line results in an oral presentation at ASCO several months ago. We also did recently announce the advancement of DLL3 TOP1 ADC into phase III registrational studies, as well as positive second-line overall survival data in small cell lung cancer at ESMO, just here recently. Mike, as you noted, the updates are going to continue. We have our first London R&D day later this afternoon at 5:00 P.M. London time, where we will showcase what we believe is a very deep pipeline in MTAP and CDKN2A. Hopefully a lot to talk about today, Mike. We look forward to the discussion.
Okay. We will preview it a little bit here in our session. But coming to the primary lead program, daro, for metastatic uveal melanoma, you filed the NDA. The filing presumably is for HLA-A2 negative patients, of which the phase III was enrolled and completed in. So talk about where you are in that filing, when would be the expected approval, and what do you expect the approval to look like?
Yeah. The NDA has been filed. We noted that that happened in the third quarter. It was towards the end of the third quarter. That was also filed under RTOR, so a rolling review submission process of the NDA. Our focus on the phase III randomized study was on the HLA-A2 negative population in the first-line setting of metastatic uveal melanoma. We have noted, based on our recent disclosures, that based on the mechanism of action as well as the data that we had presented, we do believe darovasertib is relevant irrespective of HLA-A2 status. That is how we did proceed with the NDA filing, with that specific mindset in place.
When you file it, and I've never filed an NDA, but you write out an indication, does it say HLA-A2 negative in that exact filing indication?
Yeah. As part of our NDA submission, the strategy that we are advancing is a focus on irrespective of HLA-A2 status.
Irrespective. Okay. Yeah. But we would want to emphasize that we appreciate this will be a review issue with the FDA.
Okay. Second is that we will, in either scenario, have an NCCN strategy in place Right for both the negative and the positive population.
Okay. Have you completed the rolling NDA, or maybe I might hear about that later today, I don't know. But what is the estimated PDUFA date and timing for approval?
Yeah. So we will learn on the PDUFA date here relatively soon.
At the time of NDA acceptance, we do anticipate it will be likely in that first half of next year timeframe.
Okay. Okay. When that occurs, you have filed for approval irrespective of HLA status. Most people on Wall Street would say, "Okay, wait a second." Just for those who may not know all the numbers, the reason why we are asking about this is because HLA-A2 negative is around 50/50. You might give me a different number, but it is around 50% of the target population, whereas Immunocore, another company that is actually here at this conference as well, is approved in HLA-A2 positive, the other 50%. While your indication would be going after a market that is not directly competing against Immunocore, you do believe that you could get approval for both populations and therefore double your opportunity, double, because it is in the other subgroup. Most people, investors do not know about that, but that was not what the study was enrolling. That was HLA-A2 negative. What would be the reason, and why would you say that you could get approval in both?
Yeah. Also, Michael, on the question around the prevalence or frequency of HLA-A2 negative versus positive, we do believe the majority of the population is HLA-A2 negative.
Okay. We believe it's likely in that 60/40 to two-thirds, one-third range.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
